Jaks and cytokine receptors--an intimate relationship.

Most cytokine receptors lack intrinsic kinase activity and many of them signal via Janus kinases (Jaks). These tyrosine kinases are associated with cytokine receptor subunits, they become activated upon receptor triggering and subsequently activate downstream signalling events, e.g. the phosphorylation of STAT transcription factors. The successful interplay between cytokines, their receptors and the connected Jaks not only determines signalling competence but is also vital for intracellular traffic, stability, and fate of the cognate receptors. Here, we will discuss underlying mechanisms as well as some structural features with a focus on Jak1 and two of the signal transducing receptor subunits of interleukin (IL)-6 type cytokines, gp130 and OSMR. Regions that are critically involved in Jak-binding have been identified for many cytokine receptor subunits. In most cases the membrane-proximal parts comprising the box1 and box2 regions within the receptor are involved in this association while, within Jaks, the N-terminal FERM domain, possibly together with the SH2-like domain, are pivotal for binding to the relevant receptors. The exclusive membrane localisation of Jaks depends on their ability to associate with cytokine receptors. For gp130 and Jak1, it was shown that the cytokine receptor/Jak complex can be regarded as a receptor tyrosine kinase since both molecules have the same diffusion dynamics and are virtually undissociable. Furthermore, Jaks take an active role in the regulation of the surface expression of at least some cytokine receptors, including the OSMR and this may provide a quality control mechanism ensuring that only signalling-competent receptors (i.e. those with an associated Jak) would be enriched at the cell surface.

[1]  P. Heinrich,et al.  The Jak1 SH2 Domain Does Not Fulfill a Classical SH2 Function in Jak/STAT Signaling but Plays a Structural Role for Receptor Interaction and Up-regulation of Receptor Surface Expression* , 2005, Journal of Biological Chemistry.

[2]  M. Shibamori,et al.  Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. , 2000, Immunity.

[3]  A single amino acid substitution (Trp(666)-->Ala) in the interbox1/2 region of the interleukin-6 signal transducer gp130 abrogates binding of JAK1, and dominantly impairs signal transduction. , 2000 .

[4]  I. Kerr,et al.  Jaks and Stats in signaling by the cytokine receptor superfamily. , 1995, Trends in genetics : TIG.

[5]  R. Schreiber,et al.  Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses , 1998, Cell.

[6]  Hong-Jian Zhu,et al.  A Pivotal Role for the Transmembrane Domain in Transforming Growth Factor-β Receptor Activation* , 1999, The Journal of Biological Chemistry.

[7]  A. Wilks,et al.  Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase , 1991, Molecular and cellular biology.

[8]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[9]  A. Ullrich,et al.  Proline-rich Sequence-mediated Jak2 Association to the Prolactin Receptor Is Required but Not Sufficient for Signal Transduction (*) , 1995, The Journal of Biological Chemistry.

[10]  B. Klein,et al.  Dimerization and activation of the common transducing chain (gp130) of the cytokines of the IL-6 family by mAb. , 1998, International immunology.

[11]  H. Nakauchi,et al.  Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. , 1995, Immunity.

[12]  O. Silvennoinen,et al.  JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin , 1993, Cell.

[13]  I. Wilson,et al.  Erythropoietin receptor activation by a ligand-induced conformation change. , 1999, Science.

[14]  J. Girault,et al.  Janus Kinases and Focal Adhesion Kinases Play in the 4.1 Band: A Superfamily of Band 4.1 Domains Important for Cell Structure and Signal Transduction , 1998, Molecular medicine.

[15]  I. Wilson,et al.  Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. , 1999, Science.

[16]  J. Johnston,et al.  Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID) , 1995, Nature.

[17]  A. Alcover,et al.  The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression , 2003, The EMBO journal.

[18]  P. Heinrich,et al.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.

[19]  M. Fellous,et al.  Specific Contribution of Tyk2 JH Regions to the Binding and the Expression of the Interferon α/β Receptor Component IFNAR1* , 1998, The Journal of Biological Chemistry.

[20]  P. Heinrich,et al.  Orientational Constraints of the gp130 Intracellular Juxtamembrane Domain for Signaling* , 2002, The Journal of Biological Chemistry.

[21]  S. Constantinescu,et al.  Janus Kinases Affect Thrombopoietin Receptor Cell Surface Localization and Stability* , 2005, Journal of Biological Chemistry.

[22]  J. O’Shea,et al.  Jak3-Independent Trafficking of the Common γ Chain Receptor Subunit: Chaperone Function of Jaks Revisited , 2004, Molecular and Cellular Biology.

[23]  N. Danial,et al.  Jak-STAT signaling induced by the v-abl oncogene. , 1995, Science.

[24]  P. Bates,et al.  A region encompassing the FERM domain of Jak1 is necessary for binding to the cytokine receptor gp130 , 2001, FEBS letters.

[25]  J. Marine,et al.  Jak2 Is Essential for Signaling through a Variety of Cytokine Receptors , 1998, Cell.

[26]  D. Waxman,et al.  Interaction of Growth Hormone-activated STATs with SH2-containing Phosphotyrosine Phosphatase SHP-1 and Nuclear JAK2 Tyrosine Kinase* , 1997, The Journal of Biological Chemistry.

[27]  W. Leonard,et al.  Delineation of the regions of interleukin-2 (IL-2) receptor beta chain important for association of Jak1 and Jak3. Jak1-independent functional recruitment of Jak3 to Il-2Rbeta. , 1998, The Journal of biological chemistry.

[28]  P. Karplus,et al.  Structure of the ERM Protein Moesin Reveals the FERM Domain Fold Masked by an Extended Actin Binding Tail Domain , 2000, Cell.

[29]  J. Roberts,et al.  Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. , 2001, Molecular cell.

[30]  T. Boggon,et al.  Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. , 2005, Blood.

[31]  P. Changelian,et al.  The Novel JAK‐3 Inhibitor CP‐690550 Is a Potent Immunosuppressive Agent in Various Murine Models , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[32]  B. Han,et al.  Protein 4.1R core domain structure and insights into regulation of cytoskeletal organization , 2000, Nature Structural Biology.

[33]  R. Sorenson,et al.  Prolactin receptors and JAK2 in islets of Langerhans: an immunohistochemical analysis. , 1995, Endocrinology.

[34]  Constitutive nuclear localization of Janus kinases 1 and 2. , 1996, Endocrinology.

[35]  S. Pellegrini,et al.  A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-alpha signaling. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[36]  S. Constantinescu,et al.  Structural Requirements of the Extracellular to Transmembrane Domain Junction for Erythropoietin Receptor Function* , 2005, Journal of Biological Chemistry.

[37]  J. Kere,et al.  Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. , 2005, American journal of human genetics.

[38]  H. Lodish,et al.  The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. , 2001, Molecular cell.

[39]  T. Hakoshima,et al.  Structural basis of adhesion‐molecule recognition by ERM proteins revealed by the crystal structure of the radixin—ICAM‐2 complex , 2003, The EMBO journal.

[40]  P. Changelian,et al.  The JAK3 inhibitor CP‐690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing , 2004, Journal of leukocyte biology.

[41]  J. Tavernier,et al.  Down-modulation of Type 1 Interferon Responses by Receptor Cross-competition for a Shared Jak Kinase* , 2001, The Journal of Biological Chemistry.

[42]  A. Kraft,et al.  The Amino-terminal Portion of the JAK2 Protein Kinase Is Necessary For Binding and Phosphorylation of the Granulocyte-Macrophage Colony-stimulating Factor Receptor β Chain (*) , 1995, The Journal of Biological Chemistry.

[43]  O. Silvennoinen,et al.  Regulation of the Jak2 Tyrosine Kinase by Its Pseudokinase Domain , 2000, Molecular and Cellular Biology.

[44]  P. Heinrich,et al.  Studies on the Interleukin-6-type Cytokine Signal Transducer gp130 Reveal a Novel Mechanism of Receptor Activation by Monoclonal Antibodies* , 2000, The Journal of Biological Chemistry.

[45]  R Berger,et al.  A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. , 1997, Science.

[46]  P. Heinrich,et al.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. , 1998, The Biochemical journal.

[47]  P. Heinrich,et al.  Novel Role of Janus Kinase 1 in the Regulation of Oncostatin M Receptor Surface Expression* , 2002, The Journal of Biological Chemistry.

[48]  Y. Kido,et al.  Shc phosphotyrosine-binding domain dominantly interacts with epidermal growth factor receptors and mediates Ras activation in intact cells. , 1998, Molecular endocrinology.

[49]  Jing Jiang,et al.  Janus kinase 2 enhances the stability of the mature growth hormone receptor. , 2005, Endocrinology.

[50]  P. Heinrich,et al.  Janus Kinase (Jak) Subcellular Localization Revisited , 2004, Journal of Biological Chemistry.

[51]  B. Rellahan,et al.  The Amino-Terminal Src Homology 2 Domain of Phospholipase Cγ1 Is Essential for TCR-Induced Tyrosine Phosphorylation of Phospholipase Cγ1 , 1998, The Journal of Immunology.

[52]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[53]  P. Doherty,et al.  Defective Lymphoid Development in Mice Lacking Jak3 , 1995, Science.

[54]  W. Leonard,et al.  Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. , 1995, Science.

[55]  Qingshan Li,et al.  Identification of an Acquired JAK2 Mutation in Polycythemia Vera* , 2005, Journal of Biological Chemistry.

[56]  P. Marynen,et al.  Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. , 1997, Blood.

[57]  M. Ueffing,et al.  Latent membrane protein 1 of Epstein–Barr virus interacts with JAK3 and activates STAT proteins , 1999, The EMBO journal.

[58]  P. Heinrich,et al.  Three Dileucine-like Motifs within the Interbox1/2 Region of the Human Oncostatin M Receptor Prevent Efficient Surface Expression in the Absence of an Associated Janus Kinase* , 2006, Journal of Biological Chemistry.

[59]  H. Lodish,et al.  The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. , 2001, Molecular cell.

[60]  P. Heinrich,et al.  Structural requirements of the interleukin-6 signal transducer gp130 for its interaction with Janus kinase 1: the receptor is crucial for kinase activation. , 2002, The Biochemical journal.

[61]  A. Sharpe,et al.  Defects in B Lymphocyte Maturation and T Lymphocyte Activation in Mice Lacking Jak3 , 1995, Science.

[62]  A. Cumano,et al.  Jak2 Deficiency Defines an EssentialDevelopmental Checkpoint in DefinitiveHematopoiesis , 1998, Cell.

[63]  D. Baltimore,et al.  Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo , 1992, Molecular and cellular biology.

[64]  T. Taniguchi,et al.  The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[65]  K. Yasukawa,et al.  Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[66]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[67]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[68]  Toshio Hakoshima,et al.  Structural basis of the membrane‐targeting and unmasking mechanisms of the radixin FERM domain , 2000, The EMBO journal.

[69]  Bernd Giese,et al.  Long Term Association of the Cytokine Receptor gp130 and the Janus Kinase Jak1 Revealed by FRAP Analysis* , 2003, Journal of Biological Chemistry.

[70]  S. Pellegrini,et al.  The Janus kinase family of protein tyrosine kinases and their role in signaling , 1999, Cellular and Molecular Life Sciences CMLS.

[71]  J. Rossjohn,et al.  The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. , 2006, Blood.

[72]  P. Heinrich,et al.  Different protein turnover of interleukin-6-type cytokine signalling components. , 1999, European journal of biochemistry.

[73]  H. Pircher,et al.  Partial impairment of cytokine responses in Tyk2-deficient mice. , 2000, Immunity.

[74]  M. Eck,et al.  Crystal Structure of the FERM Domain of Focal Adhesion Kinase* , 2006, Journal of Biological Chemistry.

[75]  J. Tavernier,et al.  Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130. , 1999, Journal of immunology.

[76]  I. Kerr,et al.  Mapping of a Region within the N Terminus of Jak1 Involved in Cytokine Receptor Interaction* , 2001, The Journal of Biological Chemistry.

[77]  J. Johnston,et al.  Autosomal SCID caused by a point mutation in the N‐terminus of Jak3: mapping of the Jak3–receptor interaction domain , 1999, The EMBO journal.

[78]  S. Pestka,et al.  A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses , 1997, Molecular and cellular biology.